CancerVax Corporation (NASDAQ: CNVX), a biotechnology company focused on the research, development and commercialization of biological products for the treatment of cancer, announced today its unaudited financial results for the fourth quarter and year ended December 31, 2005. For the fourth quarter ended December 31, 2005, CancerVax reported a net loss of $15.8 million, or $0.57 per share, as compared to a net loss of $14.3 million, or $0.53 per share, for the same period in 2004. For the year ended December 31, 2005, CancerVax reported a net loss of $39.6 million, or $1.42 per share, as compared to a net loss of $55.6 million, or $2.08 per share, for the same period in 2004.
